Rheumatology Book

http://www.fpnotebook.com/

Rituximab

Aka: Rituximab
  1. Indications
    1. Refractory Rheumatoid Arthritis
    2. Non-Hodgkin's Lymphoma
    3. ANCA Vasculitis
  2. Contraindications
    1. Do not use with live virus Vaccines
  3. Mechanism
    1. Monoclonal Antibody to the CD20 antigen that depletes CD20 positive B Cells
  4. Dosing
    1. Rheumatoid Arthritis: 1 gram IV every 2 weeks for 2 doses
      1. Administered with Methylprednisolone 100 mg
    2. Non-Hodgkin's Lymphoma or ANCA Vasculitis: 375 mg/m2 IV weekly for 4 doses
  5. Adverse Effects
    1. Severe infusion reactions (follows first infusion within 30-120 minutes)
    2. Tumor Lysis Syndrome
    3. Hepatitis B reactivation
    4. Renal Insufficiency
  6. Monitoring
    1. PPD before initiating therapy
    2. Complete Blood Count at initiation of therapy and then periodically after

rituximab (C0393022)

Definition (NCI_NCI-GLOSS) A drug used to treat certain types of B-cell non-Hodgkin lymphoma. It is also used with other drugs to treat chronic lymphocytic leukemia and rheumatoid arthritis. It is being studied in the treatment of other types of cancer and other conditions. Rituximab binds to a protein called CD20, which is found on B-cells, and may kill cancer cells. It is a type of monoclonal antibody.
Definition (NCI) A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
Definition (PDQ) A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42613&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=42613&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C1702" NCI Thesaurus)
Concepts Pharmacologic Substance (T121) , Amino Acid, Peptide, or Protein (T116) , Immunologic Factor (T129)
MSH C092560
SnomedCT 108809004, 386919002
English Chimeric Anti-CD20 Antibody, C2B8 Monoclonal Antibody, monoclonal antibody anti-CD20, CD20 antibody, rituximab, rituximab, rituximab (medication), rituximab [Chemical/Ingredient], riTUXimab, Rituximab Biosimilar BI 695500, BI 695500, Rituximab, Rituximab (product), Rituximab (substance), anti-CD20 monoclonal antibody, RITUXIMAB
Spanish rituximab (producto), rituximab (sustancia), rituximab
Sources
Derived from the NIH UMLS (Unified Medical Language System)


You are currently viewing the original 'fpnotebook.com\legacy' version of this website. Internet Explorer 8.0 and older will automatically be redirected to this legacy version.

If you are using a modern web browser, you may instead navigate to the newer desktop version of fpnotebook. Another, mobile version is also available which should function on both newer and older web browsers.

Please Contact Me as you run across problems with any of these versions on the website.

Navigation Tree